

Press release

SHL Telemedicine announces it is exploring dual listing on another leading Stock Exchange in the US or on the Tel Aviv Stock Exchange

The initiative intends to expand investors' access to SHL's international activity and support SHL's strategy to significantly expand the use of SmartHeartTM technology in the US

Tel Aviv / Zurich, 22 February 2021 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) ("SHL" or "the company"), a leading provider and developer of advanced personal telemedicine solutions, announced today that the company has begun exploring the possibility of dual-listing for trading on another stock exchange. The alternatives being considered by SHL include listing on a leading US stock exchange, one of the company's main target markets, as well as on the Tel Aviv Stock Exchange.

SHL is implementing its strategy for a significant expansion of the use of SmartHeart™ technology in the US, and the initiative for dual-listing on another stock exchange is intended to also make the company's activities accessible to international investors as well as expand its existing investors' base.

Further information

Elisabeth Wallimann, IRF, Phone: +41 43 244 81 41, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.